Treatment of refractory celiac disease type II (RCD II) and preventing the development of an enteropathy associated T-cell lymphoma in these patients is still difficult. In this case report, we describe a patient with RCD II who received fecal microbiota transfer as treatment for a recurrent Clostridium difficile infection, and remarkably showed a full recovery of duodenal villi and disappearance of celiac symptoms. This case suggests that altering the gut microbiota may hold promise in improving the clinical and histological consequences of celiac disease and/or RCD II.
INTRODUCTION
A small minority of patients with celiac disease develop refractory celiac disease type II (RCD II). This is a rare autoimmune condition defined by a persistent malabsorptive state, villous atrophy, and more than 20% of intraepithelial lymphocytes (IEL) with an aberrant phenotype (surface CD3-, intracellular CD3+) despite adherence to a full gluten free diet.
1 Current treatment consists of non-slow release budesonide, cladribine (a synthetic purine nucleoside homologue), and autologous stem cell transplantation. However, the prognosis is poor, with a five year mortality of about 55%. 1 Complications of RCD II include progressive malabsorption and an enteropathy associated T-cell lymphoma (EATL).
Fecal microbiota transfer (FMT) is an effective therapy for recurrent Clostridium difficile infection (CDI)
, and has shown promise in the treatment of autoimmune conditions, such as inflammatory bowel disease 3 , where the microbiome may be implicated in the disease pathology. Here, we present an unexpected promising outcome of a case of RCD II after treatment with FMT for CDI.
CASE PRESENTATION
A 68-year old woman with RCD II was admitted to the hospital because of severe diarrhea, dehydration, and malnutrition (body mass index, BMI, 17.3 kg/m2).Medical history revealed RCD II for over 10 years (villous atrophy, and >80% aberrant cells).
Except for a strict gluten free diet, the patient had refused treatment because of manageable symptoms until two years prior to admission, when additional treatment with budesonide (9 mg per day) was initiated.
Evaluation of the diarrhea included duodenoscopy and stool tests for C. difficile, Campylobacter, Salmonella, Yersinia, Shigella, Giardia, Dientamoeba fragilis, and
Cryptosporidium. Duodenal biopsies showed villous atrophy (Marsh IIIA). The stool test was positive for Cryptosporidium. The patient was treated with paromomycin for Cryptosporidium, and budesonide was continued for RCD II. Since RCD II should be considered as a low-grade lymphoma, a PET-CT was performed to rule out EATL proving negative. The patient's hospital admission was complicated by a hospitalacquired pneumonia, which was treated with a seven-day course of ceftriaxone 2000 mg intravenously. After a month of hospitalization the patient was discharged.
One month after discharge, the patient was readmitted because of severe diarrhea system. 6 Several studies on fecal samples and duodenal biopsies of celiac disease patients suggest that an imbalanced microbiota in these patients could have a pathogenic role in inducing modification of the mucosal barrier which maintains persistent immune activation, causing clinical symptoms. 7 Thereby, it was suggested that the constitutive levels of the NKG2D ligand expression on intestinal epithelial cells are also regulated by microbial signaling in the gut. 8 Despite these data regarding the role of patient's intestinal microbes in clinical symptoms and manifestation of celiac disease and RCD II, to our knowledge, manipulation of the microbiota to mitigate the pathophysiology of celiac disease and/or RCD II has not previously been performed or discussed.
In recent years, several types of treatment for RCD II have been suggested.
1
Preventing an EATL, and eliminating clinical symptoms is the goal of therapy in RCD II.
Cladribine, a synthetic purine nucleoside homologue, is supposed to be especially effective against low-grade malignancies, however, our patient did not respond to cladribine therapy, since diarrhea (> 10 UBM per day) and malnutrition persisted, and duodenal biopsies showed no reduction of aberrant cells and villous atrophy four months after the second course of cladribine. By serendipity we discovered that FMT, commonly used for CDI in recent years, might be of benefit for RCD II.
CONCLUSION
This case suggests that altering the gut microbiota may hold promise in improving the clinical and histological consequences of celiac disease and/or RCD II. It is tempting to speculate that altering the composition of the microbiota could also help restore villous atrophy. This novel treatment modality should be further investigated, particularly among patients failing to respond to cladribine treatment before performing an autologous stem cell transplantation.
